Treatment and survival of early non-metastatic breast cancer in men: real world data from a population-based registry.

Aim: This study aimed to characterize a cohort of male patients with non-metastatic breast cancer, specifically focusing on tumor characteristics, treatment strategies, and determinants of overall survival.

Methods: Data for this study were obtained from the Baden-Württemberg Cancer Registry, encompassing male patients diagnosed with breast cancer between 2015 and 2023. A total of 470 patient records were included.

Therapy of early breast cancer: current status and perspectives.

Medical advancements in breast cancer are truly remarkable. Especially in recent years, numerous new therapeutics have been approved and surgical strategies have been de-escalated for specific patient groups. In the therapeutic setting, CDK4/6 inhibitors as oral maintenance therapy in early breast cancer and immune checkpoint inhibitors (Pembrolizumab) for triple-negative breast cancer (BC) are noteworthy.

Prediction of secondary metabolites in hydroponically produced tomatoes: multivariate influence of abiotic climatic factors as well as photosynthesis and transpiration rates.

This is the first study who presents an approach to predict secondary metabolites content in tomatoes using multivariate time series classification of greenhouse sensor data, which includes climatic conditions as well as photosynthesis and transpiration rates. The aim was to find the necessary conditions in a greenhouse to determine the maximum content of secondary metabolites, as higher levels in fruits can promote human health. For this, we defined multiple classification tasks and derived suitable classification function.

Oral Maintenance Therapy in Early Breast Cancer-How Many Patients Are Potential Candidates?

Background/objectives: This single-center analysis evaluated the number of potential candidates for endocrine-based oral maintenance therapy in a real-world setting, focusing on three therapeutic agents, namely, olaparib, abemaciclib, and ribociclib, for patients with hormone receptor-positive HER2-negative early breast cancer.

Methods: All breast cancer cases from the past 10 years ( = 3230) that underwent treatment at the certified Breast Cancer Center of the Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Lübeck Campus, were analyzed.

Results: Of a total of 2038 patients with HR+ HER2- eBC, 685 patients (33.